Amgens cholesterol lowering inhibitor launched by Dr Reddy's

Dr.Reddys Laboratories today announced the launch of Repatha (evolocumab), a drug used for lowering bad cholesterol, in the country.

Repatha (evolocumab) 140 mg/ml is the only proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor available in the country, approved by the Drug Controller General India (DCGI), a press release from the drug maker said here.

PCSK9 Inhibitors are a new class of lipid lowering drugs. They target and inactivate a specific protein in the liver called proprotein convertase subtilisin kexin 9, leading to 'dramatic' reduction in the amount of harmful LDL cholesterol circulating in the bloodstream, it said.

Repatha (evolocumab) is a patented product of Amgen global and is distributed by Dr.Reddys in India, the company said.

"The launch of Repatha is another significant addition to Dr. Reddys Cardiovascular portfolio, which we believe will provide a unique treatment option to patients in India who are at risk of Heart Attack, Stroke and Coronary problems," CEO, Branded Markets (India and Emerging Markets), M V Ramana said.